<code id='A59CAD9C7F'></code><style id='A59CAD9C7F'></style>
    • <acronym id='A59CAD9C7F'></acronym>
      <center id='A59CAD9C7F'><center id='A59CAD9C7F'><tfoot id='A59CAD9C7F'></tfoot></center><abbr id='A59CAD9C7F'><dir id='A59CAD9C7F'><tfoot id='A59CAD9C7F'></tfoot><noframes id='A59CAD9C7F'>

    • <optgroup id='A59CAD9C7F'><strike id='A59CAD9C7F'><sup id='A59CAD9C7F'></sup></strike><code id='A59CAD9C7F'></code></optgroup>
        1. <b id='A59CAD9C7F'><label id='A59CAD9C7F'><select id='A59CAD9C7F'><dt id='A59CAD9C7F'><span id='A59CAD9C7F'></span></dt></select></label></b><u id='A59CAD9C7F'></u>
          <i id='A59CAD9C7F'><strike id='A59CAD9C7F'><tt id='A59CAD9C7F'><pre id='A59CAD9C7F'></pre></tt></strike></i>

          knowledge

          knowledge

          author:explore    Page View:659
          In a dark grey suit and light blue button-down shirt, Bill Sibold, CEO of Madrigal Pharmaceuticals, smiles— coverage from STAT
          Madrigal CEO Bill Sibold says the company is "interested in the patients who are most in need." Madrigal Pharmaceuticals

          The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week.

          The pill, called resmetirom, is made by Madrigal Pharmaceuticals.

          advertisement

          Metabolic dysfunction-associated steatohepatitis, or MASH and previously called NASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          ReNAgade cuts staff seven months after raising $300 million
          ReNAgade cuts staff seven months after raising $300 million

          AdobeBiotechstartupReNAgadeTherapeuticsiscuttingstaffjustsevenmonthsafterraisingthelargestSeriesArou

          read more
          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more

          Group opposing PBM reform sets lobbying record

          Aconservativegroupadvocatingagainstchanginghowpharmacymiddlemenoperatespentmorethan$1milliononlobbyi